Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial (vol 75, pg 1080, 2018)

被引：0
|
作者：
Stauffer, V. L.
Dodick, D. W.
Zhang, Q.
Carter, J. N.
Ailani, J.
Conley, R. R.
机构：
来源：
JAMA NEUROLOGY | 2019年 / 76卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：872 / 872
页数：1
相关论文
共 50 条
  • [21] Changes in patient functioning and disability: results from two phase 3 double-blind placebo-controlled clinical trials evaluating galcanezumab for episodic migraine prevention (EVOLVE-1 and EVOLVE-2)
    Ford, Janet H.
    Ayer, David W.
    Zhang, Qi
    Carter, Jeffrey N.
    Skljarevski, Vladimir
    Aurora, Sheena K.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [22] Persistence of Effect of Galcanezumab in Patients with Episodic or Chronic Migraine: Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1,-2 and REGAIN Studies
    Aurora, S.
    Zhang, Q.
    HEADACHE, 2018, 58 : 177 - 178
  • [23] Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial
    Schwedt, Todd J.
    Oakes, Tina M. Myers
    Martinez, James M.
    Vargas, Bert B.
    Pandey, Hitendra
    Pearlman, Eric M.
    Richardson, Diane R.
    Varnado, Oralee J.
    Meyer, Michael Cobas
    Goadsby, Peter J.
    NEUROLOGY AND THERAPY, 2024, 13 (01) : 85 - 105
  • [24] Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial
    Todd J. Schwedt
    Tina M. Myers Oakes
    James M. Martinez
    Bert B. Vargas
    Hitendra Pandey
    Eric M. Pearlman
    Diane R. Richardson
    Oralee J. Varnado
    Michael Cobas Meyer
    Peter J. Goadsby
    Neurology and Therapy, 2024, 13 : 85 - 105
  • [25] Analysis of Initial Non Responders to Galcanezumab in Patients with Episodic or Chronic Migraine: Results from the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Trials
    Nichols, Russell M.
    Ruff, Dustin
    Pearlman, Eric
    Aurora, Sheena K.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [26] Galcanezumab: A Review in the Prevention of Migraine and Treatment of Episodic Cluster Headache (vol 80, pg 893, 2020)
    Scott, Lesley J.
    DRUGS, 2020, 80 (13) : 1379 - 1379
  • [27] Analysis of Initial Non-Responders to Galcanezumab in Patients with Episodic or Chronic Migraine: Results from the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Trials
    Nichols, R.
    Ruff, D.
    Pearlman, E.
    Aurora, S.
    HEADACHE, 2018, 58 : 173 - 174
  • [28] Evaluation of Cardiovascular Outcomes in Adult Patients With Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1, EVOLVE-2, and REGAIN Studies
    Oakes, Tina M.
    Kovacs, Richard
    Rosen, Noah
    Doty, Erin
    Kemmer, Phebe
    Aurora, Sheena K.
    Camporeale, Angelo
    HEADACHE, 2020, 60 (01): : 110 - 123
  • [29] 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies
    Rosen, Noah
    Pearlman, Eric
    Ruff, Dustin
    Day, Kathleen
    Nagy, Abraham Jim
    HEADACHE, 2018, 58 (09): : 1347 - 1357
  • [30] GALCANEZUMAB EFFECTS IN ADULT PATIENTS WITH EPISODIC OR CHRONIC MIGRAINE ARE PERSISTENT: DATA FROM THREE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EVOLVE-1, EVOLVE-2, AND REGAIN STUDIES
    Aurora, S.
    Zhang, Q.
    Stauffer, V.
    CEPHALALGIA, 2018, 38 : 50 - 51
12345